middle.news
Opthea Completes Final COAST Trial Visit Ahead of Crucial Q2 Data
7:12am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Opthea Completes Final COAST Trial Visit Ahead of Crucial Q2 Data
7:12am on Monday 2nd of June, 2025 AEST
Key Points
Final week 52 patient visit completed in COAST Phase 3 trial
Trial tests sozinibercept plus aflibercept versus standard care in wet AMD
Topline results anticipated in early Q2 calendar year 2025
Concurrent ShORe trial with ranibizumab ongoing, results mid-2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE